CA3227534A1 — Radiolabeled compound and use thereof
Assigned to University of Osaka NUC · Expires 2023-02-02 · 3y expired
What this patent protects
The purpose of the present invention is to provide a drug which specifically binds to PSMA, which is effective in treatment and diagnosis of tumors or cancers that express PSMA, such as treatment and diagnosis of prostate cancer, especially castration-resistant prostate cancer (C…
USPTO Abstract
The purpose of the present invention is to provide a drug which specifically binds to PSMA, which is effective in treatment and diagnosis of tumors or cancers that express PSMA, such as treatment and diagnosis of prostate cancer, especially castration-resistant prostate cancer (CRPC), and further especially castration-resistant prostate cancer with metastasis (mCRPC), and which does not produce any side effects due to accumulation in the kidney and salivary glands.?The present invention provides a radiolabeled compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The present invention is represented by formula (I). (I) [In the formula, each symbol is as defined in the description.]
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.